The effect of iron deficiency on cardiac resynchronization therapy: results from the RIDE-CRT Study.
Cardiac resynchronization therapy
Heart failure
Iron deficiency
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
26
09
2019
revised:
09
02
2020
accepted:
19
02
2020
pubmed:
20
3
2020
medline:
22
6
2021
entrez:
20
3
2020
Statut:
ppublish
Résumé
Cardiac resynchronization therapy (CRT) improves functional status, induces reverse left ventricular remodelling, and reduces hospitalization and mortality in patients with symptomatic heart failure, left ventricular systolic dysfunction, and QRS prolongation. However, the impact of iron deficiency on CRT response remains largely unclear. The purpose of the study was to assess the effect of functional and absolute iron deficiency on reverse cardiac remodelling, clinical response, and outcome after CRT implantation. The relation of iron deficiency and cardiac resynchronization therapy response (RIDE-CRT) study is a prospective observational study. We enrolled 77 consecutive CRT recipients (mean age 71.3 ± 10.2 years) with short-term follow-up of 3.3 ± 1.9 months and long-term follow-up of 13.0 ± 3.2 months. Primary endpoints were reverse cardiac remodelling on echocardiography and clinical CRT response, assessed by change in New York Heart Association classification. Echocardiographic CRT response was defined as relative improvement of left ventricular ejection fraction ≥ 20% or left ventricular global longitudinal strain ≥ 20%. Secondary endpoints were hospitalization for heart failure and all-cause mortality (mean follow-up of 29.0 ± 8.4 months). At multivariate analysis, iron deficiency was identified as independent predictor of echocardiographic (hazard ratio 4.97; 95% confidence interval 1.15-21.51; P = 0.03) and clinical non-response to CRT (hazard ratio 4.79; 95% confidence interval 1.30-17.72, P = 0.02). We found a significant linear-by-linear association between CRT response and type of iron deficiency (P = 0.004 for left ventricular ejection fraction improvement, P = 0.02 for left ventricular global longitudinal strain improvement, and P = 0.003 for New York Heart Association response). Iron deficiency was also significantly associated with an increase in all-cause mortality (P = 0.045) but not with heart failure hospitalization. Iron deficiency is a negative predictor of effective CRT therapy as assessed by reverse cardiac remodelling and clinical response. Assessment of iron substitution might be a relevant treatment target to increase CRT response and outcome in chronic heart failure patients.
Identifiants
pubmed: 32189474
doi: 10.1002/ehf2.12675
pmc: PMC7261541
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1072-1084Subventions
Organisme : Medtronic Research Grant
Pays : International
Informations de copyright
© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.
Références
Circulation. 2011 Mar 15;123(10):1061-72
pubmed: 21357819
Trends Cardiovasc Med. 2019 Aug;29(6):335-342
pubmed: 30401603
Clin Sci (Lond). 2005 Sep;109(3):277-86
pubmed: 15877545
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Eur Heart J Cardiovasc Imaging. 2015 Jan;16(1):1-11
pubmed: 25525063
Circulation. 2013 Nov 26;128(22):2407-18
pubmed: 24276876
Eur J Heart Fail. 2009 Apr;11(4):391-9
pubmed: 19261620
Circ Res. 2011 Sep 16;109(7):750-7
pubmed: 21817160
N Engl J Med. 2005 Apr 14;352(15):1539-49
pubmed: 15753115
Eur J Heart Fail. 2014 Oct;16(10):1125-32
pubmed: 25208495
N Engl J Med. 2010 Dec 16;363(25):2385-95
pubmed: 21073365
Eur J Heart Fail. 2016 Jul;18(7):798-802
pubmed: 27030541
N Engl J Med. 2014 May 1;370(18):1694-701
pubmed: 24678999
Eur Heart J. 2015 Mar 14;36(11):657-68
pubmed: 25176939
J Am Coll Cardiol. 2008 Jan 15;51(2):103-12
pubmed: 18191732
Eur Heart J. 2013 Mar;34(11):816-29
pubmed: 23100285
Biochim Biophys Acta. 2009 Jul;1790(7):629-36
pubmed: 18948172
Am J Cardiol. 2006 Jan 15;97(2):260-3
pubmed: 16442375
Circ J. 2011;75(3):521-7
pubmed: 21325727
Am Heart J. 2013 Apr;165(4):575-582.e3
pubmed: 23537975
Europace. 2018 Aug 1;20(8):1303-1311
pubmed: 29016821
Eur Heart J. 2013 Aug;34(29):2281-329
pubmed: 23801822
Eur Heart J. 2013 Dec;34(46):3547-56
pubmed: 23900696
ESC Heart Fail. 2020 Jun;7(3):1072-1084
pubmed: 32189474
Heart Rhythm. 2014 Sep;11(9):1619-25
pubmed: 24893122
Cardiology. 2014;128(4):320-6
pubmed: 24924145
Am J Cardiol. 2017 Jan 1;119(1):65-70
pubmed: 27780556
Eur J Heart Fail. 2018 Jan;20(1):125-133
pubmed: 28436136
Int J Cardiol. 2016 Nov 1;222:133-134
pubmed: 27494725
World Health Organ Tech Rep Ser. 1968;405:5-37
pubmed: 4975372
J Am Coll Cardiol. 2009 Mar 3;53(9):765-73
pubmed: 19245967
N Engl J Med. 2002 Jun 13;346(24):1845-53
pubmed: 12063368
N Engl J Med. 2009 Dec 17;361(25):2436-48
pubmed: 19920054
Eur Heart J Cardiovasc Imaging. 2012 Sep;13(9):763-75
pubmed: 22379129
Eur J Heart Fail. 2017 Apr;19(4):522-530
pubmed: 27647766
J Am Coll Cardiol. 2006 Dec 19;48(12):2485-9
pubmed: 17174186
Eur Heart J. 2010 Aug;31(15):1872-80
pubmed: 20570952
Int J Cardiol. 2018 Jun 15;261:114-118
pubmed: 29580659
Pacing Clin Electrophysiol. 2008 Nov;31(11):1475-99
pubmed: 18950306
Circ Cardiovasc Genet. 2010 Feb;3(1):78-87
pubmed: 20160199
J Card Fail. 2011 Nov;17(11):899-906
pubmed: 22041326
Heart Fail Clin. 2010 Jul;6(3):295-304
pubmed: 20630404
Circulation. 2017 Oct 10;136(15):1374-1383
pubmed: 28701470
Int J Cardiol. 2014 Jun 15;174(2):268-75
pubmed: 24768464